These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28134399)
1. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics]. Brardi S; Ponchietti R; Duranti E G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399 [TBL] [Abstract][Full Text] [Related]
2. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Brardi S; Cevenini G; Verdacchi T; Romano G; Ponchietti R Arch Ital Urol Androl; 2015 Mar; 87(1):66-71. PubMed ID: 25847900 [TBL] [Abstract][Full Text] [Related]
3. Cinacalcet for the treatment of primary hyperparathyroidism. Dillon ML; Frazee LA Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675 [TBL] [Abstract][Full Text] [Related]
4. [The effects of Cinacalcet in renal stone formers with primary hyperparathyroidism]. Vitale C; Bermond F; Rodofili A; Soragna G; Marcuccio C; Tricerri A; Marangella M G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545632 [TBL] [Abstract][Full Text] [Related]
5. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. Vera L; Oddo S; Di Iorgi N; Bentivoglio G; Giusti M J Med Case Rep; 2016 Dec; 10(1):361. PubMed ID: 27998296 [TBL] [Abstract][Full Text] [Related]
6. [Medical treatment of primary hyperparathyroidism: role of calcimimetics]. Muñoz Torres M; García Martín A Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758 [TBL] [Abstract][Full Text] [Related]
7. Benefits and place of calcimimetics in the management of primary hyperparathyroidism. Meier C Ann Endocrinol (Paris); 2015 May; 76(2):163-4. PubMed ID: 25913524 [No Abstract] [Full Text] [Related]
8. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Akinci B; Comlekci A; Tankurt E Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096 [TBL] [Abstract][Full Text] [Related]
9. Medical management of primary hyperparathyroidism. Khan AA J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743 [TBL] [Abstract][Full Text] [Related]
10. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106 [TBL] [Abstract][Full Text] [Related]
11. Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review. Sabbadin C; Donà G; Bordin L; Iacobone M; Camozzi V; Mian C; Armanini D BMC Endocr Disord; 2015 Jan; 15():4. PubMed ID: 25631825 [TBL] [Abstract][Full Text] [Related]
12. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587 [TBL] [Abstract][Full Text] [Related]
13. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714 [TBL] [Abstract][Full Text] [Related]
14. Current opinions on nephrolithiasis associated with primary hyperparathyroidism. Cong X; Shen L; Gu X Urolithiasis; 2018 Oct; 46(5):453-457. PubMed ID: 29350243 [TBL] [Abstract][Full Text] [Related]
15. Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population. Pierreux J; Bravenboer B Horm Metab Res; 2018 Nov; 50(11):797-802. PubMed ID: 30396209 [TBL] [Abstract][Full Text] [Related]
16. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Khan A; Grey A; Shoback D J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912 [TBL] [Abstract][Full Text] [Related]
17. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function. Nguyen S; Gosmanova EO; Gosmanov AR J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691 [TBL] [Abstract][Full Text] [Related]
18. Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics. Foppiani L; Bottoni G; Piccardo A Acta Medica (Hradec Kralove); 2019; 62(4):156-160. PubMed ID: 32036848 [TBL] [Abstract][Full Text] [Related]
19. Primary Hyperparathyroidism: Effects on Bone Health. Zanocco KA; Yeh MW Endocrinol Metab Clin North Am; 2017 Mar; 46(1):87-104. PubMed ID: 28131138 [TBL] [Abstract][Full Text] [Related]
20. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]